医脉通编译整理，未经授权请勿转载

2019年5月31日-6月4日，一年一度的美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）年会即将在芝加哥召开。本次大会上最重要的研究是什么呢？当地时间6月2日，全体大会专场上将公布4项最重要的研究LBA1~4，让我们一睹为快！

Abstract LBA1

 

Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.

《评价医疗法案》医疗补助计划扩大对癌症治疗种族差异的影响。

Blythe J.S.Adamson,PhD,MPH-First Author

Flatiron Health

Jun 02, 1:45 PM-2:00 PM , Location：Hall B1

Abstract  LBA2 

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

标准治疗联合或不联合恩杂鲁胺用于转移性激素敏感性前列腺癌（mHSPC）的III期随机临床研究的总生存（OS）结果。

Christopher Sweeney, MBBS - First Author

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Jun 02, 2:15 PM - 2:30 PM，Location: Hall B1

Abstract  LBA3

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

ANNOUNCE：一项关于多柔比星+奥拉单抗对比多柔比星+安慰剂用于晚期软组织肉瘤的随机安慰剂对照的III期临床研究。

William D. Tap, MD - First Author

Memorial Sloan Kettering Cancer Center

Jun 02, 2:45 PM - 3:00 PM，Location: Hall B1

Abstract LBA4

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

奥拉帕尼用于一线铂类为基础化疗后种系BRCA突变转移性胰腺癌维持治疗的III期临床研究（III期POLO研究）。

Hedy L. Kindler, MD, FASCO - First Author

The University of Chicago，

Jun 02, 3:15 PM - 3:30 PM，Location: Hall B1

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)